vs
STANDARD BIOTOOLS INC.（LAB）与TRX GOLD Corp（TRX）财务数据对比。点击上方公司名可切换其他公司
TRX GOLD Corp的季度营收约是STANDARD BIOTOOLS INC.的1.3倍（$25.1M vs $19.6M），TRX GOLD Corp净利率更高（-2.0% vs -177.4%，领先175.4%），TRX GOLD Corp同比增速更快（100.5% vs -11.5%），过去两年TRX GOLD Corp的营收复合增速更高（64.2% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
TRX黄金公司是一家矿产勘探开发企业，核心业务聚焦黄金资源的勘探与开发，主要运营区域位于东非，在坦桑尼亚持有核心项目资产，瞄准高品位矿床推动可持续生产，为利益相关方创造长期价值。
LAB vs TRX — 直观对比
营收规模更大
TRX
是对方的1.3倍
$19.6M
营收增速更快
TRX
高出112.0%
-11.5%
净利率更高
TRX
高出175.4%
-177.4%
两年增速更快
TRX
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $25.1M |
| 净利润 | $-34.7M | $-496.0K |
| 毛利率 | 48.5% | 56.6% |
| 营业利润率 | -168.5% | — |
| 净利率 | -177.4% | -2.0% |
| 营收同比 | -11.5% | 100.5% |
| 净利润同比 | -28.8% | -123.2% |
| 每股收益（稀释后） | $-0.09 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABTRX
| Q4 25 | — | $25.1M | ||
| Q3 25 | $19.6M | — | ||
| Q2 25 | $21.8M | $12.5M | ||
| Q1 25 | $40.8M | $9.1M | ||
| Q4 24 | — | $12.5M | ||
| Q3 24 | $22.1M | — | ||
| Q2 24 | $22.5M | $10.1M | ||
| Q1 24 | $45.5M | $8.0M |
净利润LABTRX
| Q4 25 | — | $-496.0K | ||
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-33.5M | $1.1M | ||
| Q1 25 | $-26.0M | $-1.9M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-26.9M | — | ||
| Q2 24 | $-45.7M | $-1.7M | ||
| Q1 24 | $-32.2M | $1.9M |
毛利率LABTRX
| Q4 25 | — | 56.6% | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | 35.1% | ||
| Q1 25 | 48.4% | 23.5% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | 42.9% | ||
| Q1 24 | 53.1% | 41.0% |
营业利润率LABTRX
| Q4 25 | — | — | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | — | ||
| Q1 25 | -80.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -120.9% | — | ||
| Q2 24 | -134.5% | — | ||
| Q1 24 | -132.2% | — |
净利率LABTRX
| Q4 25 | — | -2.0% | ||
| Q3 25 | -177.4% | — | ||
| Q2 25 | -153.7% | 8.9% | ||
| Q1 25 | -63.8% | -21.3% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | -122.0% | — | ||
| Q2 24 | -203.3% | -16.3% | ||
| Q1 24 | -70.6% | 24.1% |
每股收益（稀释后）LABTRX
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | $0.00 | ||
| Q1 25 | $-0.07 | $-0.01 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.12 | $-0.01 | ||
| Q1 24 | $-0.27 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $9.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $74.5M |
| 总资产 | $539.6M | $129.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABTRX
| Q4 25 | — | $9.2M | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | $3.6M | ||
| Q1 25 | $150.9M | $6.0M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | $7.7M | ||
| Q1 24 | $287.1M | $8.0M |
总债务LABTRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABTRX
| Q4 25 | — | $74.5M | ||
| Q3 25 | $399.7M | — | ||
| Q2 25 | $424.5M | $69.0M | ||
| Q1 25 | $454.6M | $67.5M | ||
| Q4 24 | — | $68.4M | ||
| Q3 24 | $489.3M | — | ||
| Q2 24 | $510.3M | $62.5M | ||
| Q1 24 | $577.3M | $63.9M |
总资产LABTRX
| Q4 25 | — | $129.6M | ||
| Q3 25 | $539.6M | — | ||
| Q2 25 | $557.0M | $112.3M | ||
| Q1 25 | $579.6M | $106.7M | ||
| Q4 24 | — | $102.6M | ||
| Q3 24 | $681.5M | — | ||
| Q2 24 | $708.7M | $92.6M | ||
| Q1 24 | $777.7M | $88.2M |
负债/权益比LABTRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $4.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABTRX
| Q4 25 | — | $4.0M | ||
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | $3.4M | ||
| Q1 25 | $-30.3M | $2.0M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-39.0M | $3.1M | ||
| Q1 24 | $-62.5M | $1.0M |
自由现金流LABTRX
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABTRX
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABTRX
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
现金转化率LABTRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.10× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
TRX
暂无分部数据
